Ken Griffin Graybug Vision, Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.13 - $1.93 $8,664 - $14,799	-7,668 Reduced 12.94%	51,605 $63,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $3.6 $38,793 - $80,262	-22,295 Reduced 27.33%	59,273 $108,000
Q3 2021 Nov 15, 2021	BUY	$3.18 - $5.17 $259,386 - $421,706	81,568 New	81,568 $271,000
Q4 2020 Feb 16, 2021	SELL	$13.05 - $33.93 $5.09 Million - $13.2 Million	-390,289 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$12.71 - $16.5 $4.96 Million - $6.44 Million	390,289 New	390,289 $4.96 Million

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.